Nyrada Inc - Annual Report 2021

NYRADA INC (ASX:NYR) 26 Relationship between the Remuneration Policy and Consolidated Entity performance The Board considers that at this time, evaluation of the Consolidated Entity financial performance using generally accepted measures such as profitability, total shareholder return or benchmarking are not relevant as the Consolidated Entity is in the preclinical phase of drug development. Short-term employee benefits Post- employment benefits Share- based payments Salary & fees Bonus Other Super- annuation Options 4 Total 2021 $ $ $ $ $ $ Non-Executive Directors John Moore 130,101 - - - 182,564 312,665 Graham Kelly 1 5,189 - - 493 191,780 197,462 Peter Marks 49,522 - - - 91,282 140,804 Rüdiger Weseloh 3 66,906 - - - 91,282 158,188 Marcus Frampton 51,887 - - - 91,282 143,169 Christopher Cox 51,887 - - - 91,282 143,169 Ian Dixon 2 40,800 - - - 69,168 109,968 Executive Employees James Bonnar (CEO) 277,177 - 18,163 23,948 58,757 378,045 Total 673,469 - 18,163 24,441 867,397 1,583,470 1 Graham Kelly resigned as Non-Executive Director on 8 September 2020. 2 Ian Dixon was appointed as Non-Executive Director on 8 September 2020. 3 Rüdiger Weseloh was remunerated $22,268 for services provided outside of his Director role for R&D consulting. The fees paid were at market rates. 4 The value included in the share-based payment options column is calculated using sophisticated financial models. The expense is apportioned from the grant date to the date the options vest. As at the date of this report no KMP options have been exercised and this amount does not represent a cash benefit to the KMP.